Signal Transduction
Stem Cells
Signaling Pathways
Product Type
All Products
New Products
Small Molecules
Peptides
Controlled Substances
Toxins
Caged Compounds
Fluorescent Probes
Screening Libraries
Ligand Sets
Other Product Types
Research Area
Cancer
Cardiovascular System
Endocrinology
Immunology
Neuroscience
Pain & Inflammation
Respiratory System
ThalidomideCat. No. 0652 |
Price and AvailabilityBy clicking submit you agree to accept a cookie from Tocris Bioscience. For details, please read our privacy and cookie policy. |
|
Chemical Name: N-(2,6-dioxo-3-piperidinyl)phthalimide |
Biological Activity
Teratogen, sedative-hypnotic with inherent anti-inflammatory properties. A selective inhibitor of tumor necrosis factor α (TNF-α) synthesis.Certificate of Analysis / Safety Data Sheet
References
Merck Index 12 9390.
Sampaio et al (1991) Thalidomide selectively inhibits tumor necrosis factor α production by stimulated human monocytes. J.Exp.Med. 173 699. PMID: 1997652.
Makonkawkeyoon et al (1993) Thalidomide inhibits the replication of human-immunodeficiency-virus type 1. Proc.Natl.Acad.Sci.U.S.A. 90 5974. PMID: 8327469.
Kanbayashi et al (1996) Thalidomide, a hypnotic with immune modulating properties, increases cataplexy in canine narcolepsy. Neuroreport 7 1881. PMID: 8905685.
Boireau et al (1997) Thalidomide reduces MPTP-induced decrease in striatal dopamine levels in mice. Neurosci.Lett. 234 123. PMID: 9364513.
Zhang et al (2008) Thalidomide influences growth and vasculogenic mimicry channel formation in melanoma. J.Exp.Clin.Cancer Res. 27 60. PMID: 18983651.
If you know of a relevant citation for this product please let us know.
View Related Products by Target
Keywords: Thalidomide, supplier, TNF-α, TNF-alpha, synthesis, inhibitors, Interleukins, Tumor, Necrosis, Factor-α, Factor-alpha, Cytokines, Signaling, Signalling, teratogen, anti-inflammatory
Quick Order
Find multiple products by catalog number
Cancer Research Guide
Request your free copy
Highlights over 350 products for cancer research. Request a copy or view PDF today.
Immunology Guide
Highlights over 150 products for immunology research. Request a copy or view PDF today.
New Therapies and Challenges in Asthma
Written by Peter J. Barnes
'New Therapies, Challenges, and Breakthroughs in Asthma' highlights key pathways and new therapies used to treat asthma, including those currently in clinical development.
VEGF Pathway & Anti-Angiogenic Therapy
Written by N. Ferrara & Y. Crawford
A summary of antiangiogenic therapies targeting the VEGF pathway and the mechanisms of therapy resistance.
New Products in this Area
Inhibitor of NF-kB activation; also inhibits SXC
CID 2858522Selectively inhibits PKC-induced NF-κB activation
20% Discount*
Potent, selective LRRK2 inhibitor
Tocris is the first to launch GSK2578215A, licensed from GlaxoSmithKline, for the study of Parkinson's Disease.